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Introduction
The clinical management of human immunodeficiency virus 
(HIV) infection is evolving rapidly and it is a challenge to ensure 
that clinical practice guidelines remain up to date, valid and 
evidence-based. Yet, this is a prerequisite for high-quality care.1,2
Since 2003, the World Health Organization (WHO) has 
developed and regularly revised global recommendations for 
postexposure HIV prophylaxis, the prevention of mother-to-
child HIV transmission and antiretroviral therapy (ART) for 
adults, adolescents and children.3–6 In individual countries, 
the effective implementation of HIV clinical services relies on 
national acquired immunodeficiency syndrome (AIDS) pro-
grammes developing and updating national guidelines, usually 
by either adopting or adapting international reference guidelines 
or by de novo guideline development. These strategies must 
employ rigorous methodologies to ensure the validity of the 
resulting guidelines.7–9
While assisting countries in the WHO Eastern Mediterra-
nean Region with national HIV guideline development, WHO 
regional officers observed that national guideline development 
groups found it difficult to adopt a systematic approach. Con-
sequently, they felt that the resulting national guidelines were 
suboptimal and, moreover, that the lack of a systematic approach 
hampered the process of external review by WHO regional of-
ficers. Similar observations have been made previously about 
local guideline adaptations in other medical fields.10,11
In response, the WHO Regional Office for the Eastern 
Mediterranean, in collaboration with the United Nations Chil-
dren’s Fund (UNICEF) Middle East and North Africa Regional 
Office, proposed that national AIDS programmes in the region 
should organize a review of all HIV clinical practice guidelines 
developed locally. The purpose was threefold: to gain insight into 
the challenges of national HIV clinical guideline development 
and adaptation; to appraise the guideline development meth-
odologies used and the concordance of the guidelines’ content 
with WHO 2006 and 2007 global recommendations;3–6 and 
to enhance regional capacity for sound guideline development 
and appraisal. The review was not intended to evaluate guideline 
implementation at the service delivery level.
This paper reports the main findings of the review of 
national HIV clinical guidelines from countries in the eastern 
Mediterranean.
Methods
Guideline review process
The WHO Regional Office for the Eastern Mediterranean pro-
posed a review of HIV clinical practice guidelines to members of 
national AIDS programmes in the region and asked an academic 
partner, the Institute of Tropical Medicine in Antwerp, Belgium, 
to guide the process. In October 2008, the review’s objectives 
and modalities were discussed with a group of regional and 
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Objective To appraise the process of development and clinical content of national human immunodeficiency virus (HIV) clinical practice 
guidelines of countries in the eastern Mediterranean and to formulate recommendations for future guideline development and adaptation.
Methods Twenty-three countries in the World Health Organization (WHO) Eastern Mediterranean and United Nations Children’s Fund 
Middle East and North Africa regions were invited to submit national HIV clinical practice guidelines for review. The guideline development 
methodology was assessed using an adaptation of the Appraisal of Guidelines Research and Evaluation (AGREE) instrument and guideline 
content, using a checklist to evaluate concordance with WHO 2006 generic guidelines.
Findings Twelve countries submitted 20 guidelines developed between 2004 and 2009. Median scores were poor (i.e. < 0.6) for the 
methodological quality domains of rigour of development, stakeholder involvement and applicability and flexibility. Scores were better 
for the domains of scope and purpose (median: 0.82, interquartile range, IQR: 0.58–0.89) and clarity and presentation (median: 0.67, 
IQR: 0.50–0.78). Concerning guideline content, recommended first-line treatment and eligibility criteria for antiretroviral therapy (ART) 
in adults were in line with WHO recommendations in most guidelines. However, recommendations on antiretroviral prophylaxis for the 
prevention of vertical HIV transmission, diagnosis and treatment of HIV infection in infants, monitoring patients on ART, treatment failure 
and co-morbidities were often lacking.
Conclusion The large majority of national HIV clinical practice guidelines had methodological weaknesses and content inaccuracies. 
Countries require assistance with the adaptation process to ensure that guidelines are valid and up to date and accurately reflect WHO 
global clinical care recommendations for patients with HIV.
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international HIV experts, including 
representatives of the WHO Regional 
Office for the Eastern Mediterranean, 
the UNICEF Middle East and North 
Africa Regional Office, WHO head-
quarters and the Institute of Tropical 
Medicine in Antwerp. By May 2009, 
the national AIDS programmes of all 
23 countries in either the WHO Eastern 
Mediterranean Region or the UNICEF 
Middle East and North Africa Region 
(Box 1) had been invited to submit 
their HIV clinical practice guidelines 
on the prevention of mother-to-child 
transmission, postexposure prophylaxis, 
clinical management of HIV infections 
including the treatment and prevention 
of opportunistic infections, and ART for 
adults and children.
After submission of the guidelines, 
the key informants of the national AIDS 
programmes were asked to complete a 
49-item country questionnaire on the 
process involved in developing individual 
clinical practice guidelines. The question-
naire responses were sent to the reviewers 
together with the guidelines. Five teams 
of regional and international reviewers, 
hereafter referred to as the guideline re-
view group, independently evaluated the 
development methodology and clinical 
content of the guidelines.
Two appraisal tools were developed 
for the guideline review: the process of 
guideline development was assessed us-
ing an adapted version of the Appraisal 
of Guidelines Research and Evaluation 
(AGREE) instrument from the AGREE 
Collaboration12 and guideline content 
was assessed by comparison with WHO 
2006 and 2007 global recommendations 
on HIV treatment.3–6 The methodol-
ogy and content of the guidelines were 
appraised by at least two reviewers. To 
ensure that any inconsistencies between 
different guidelines from a single coun-
try were identified, the same reviewers 
appraised the methodology and content 
of all guidelines submitted by that coun-
try. To ensure impartiality, none of the 
reviewers appraised guidelines that he or 
she had helped to develop or adapt.
All data from the country question-
naires and on guideline methodology 
and content were entered into an Access 
database (Microsoft Corporation, Red-
mond, USA).
During a consensus workshop in 
June 2009, the guideline review group 
discussed the methodolog y of the 
review process and the results of the 
review. In addition, recommendations 
for future local guideline development 
and adaptation were formulated follow-
ing a discussion of the review’s findings 
with representatives of national AIDS 
programmes, WHO country, regional 
and headquarters staff and HIV experts 
from the region.
Guideline review and appraisal 
tools
The guideline development methodology 
was appraised using a tool based on the 
framework of the AGREE Collaboration 
instrument and incorporating elements 
of a Joint United Nations Programme 
on HIV/AIDS (UNAIDS) document 
entitled Developing HIV/AIDS treat-
ment guidelines.13 The appraisal tool 
included 33 items (Table 1) that were 
scored using a 4-point Likert scale (i.e. 
4 = strongly agree, 3 = agree, 2 = disagree 
and 1 = strongly disagree) and grouped 
into five quality domains: scope and 
purpose, stakeholder involvement, rigour 
of development, clarity and presentation, 
and clinical applicability and flexibility. 
To help users understand the items, docu-
mentation provided with the tool con-
tained explanatory examples. Reviewers 
scored clinical practice guidelines using 
information about the guideline develop-
ment process contained in the guideline 
documents themselves or obtained from 
country questionnaires.
Mean scores on the five quality do-
mains were calculated in accordance with 
AGREE procedures,12 with standardized 
scores ranging from 0 (lowest) to 1 (high-
est). There is no accepted threshold for 
differentiating between high- and low-
quality guidelines with AGREE instru-
ment scores.14,15 However, for our analysis 
we set a domain score threshold of 0.60 as 
indicating “reasonable” quality.
Guideline content was appraised 
using a concordance checklist (available 
from: http://telemedicine.itg.be/tele-
medicine/uploads/contentreview_check-
list.pdf ) divided into five sections dealing 
with specific topics: postexposure prophy-
laxis, the prevention of mother-to-child 
HIV transmission, clinical management, 
ART in adults and ART in children. 
Each section contained a comprehensive 
list of programmatic and clinical recom-
mendations based on WHO guidelines 
from 2006 and 2007 and subsequent 
publications.3–6,16–22 The reviewer had 
to verify whether each recommendation 
was included in the national guidelines 
and was accurate and up to date. In ad-
dition, any gaps in clinical content were 
identified.
For this paper, the analysis of the 
concordance between national guidelines 
and WHO recommendations was limited 
to selected core recommendations on the 
prevention of mother-to-child HIV trans-
mission, ART in adults and paediatric 
ART. A more extensive analysis of concor-
dance was judged inappropriate because 
of the imminent revision of WHO global 
guidelines, which will require countries to 
adapt their clinical practice guidelines in 
the near future.
The final assessment of national 
HIV clinical practice guidelines was 
based on an analysis of the review results 
and ensuing discussions at the consensus 
meeting.
Results
Guidelines were submitted by 14 national 
AIDS programmes from the 23 countries 
invited to participate in the review. Two 
submissions were not retained: the first 
because an electronic copy was not avail-
able and the second because it was an exact 
copy of non-WHO reference guidelines, 
which made the concordance and meth-
odological review less informative. The 12 
participating national AIDS programmes, 
which are referred to as programmes A to 
L in Table 2, submitted a total of 20 sets 
of guidelines: 13 were topic-specific (e.g. 
Box 1. Countries in the Eastern Mediterranean Region of the World Health 
Organization or the Middle East and North Africa Region of the United Nations 
Children’s Fund, 2009
Afghanistan,a Algeria,b Bahrain, Djibouti, Egypt, Islamic Republic of Iran, Iraq, Jordan, Kuwait, 
Lebanon, Libyan Arab Jamahiriya, Morocco, Oman, Pakistan,a Qatar, Saudi Arabia, Somalia,a 
Sudan,c Syrian Arab Republic, Tunisia, United Arab Emirates, West Bank and Gaza Strip, Yemena
a Afghanistan, Pakistan and Somalia are part of the WHO Eastern Mediterranean Region but not the UNICEF 
Middle East and North Africa Region.
b Algeria is part of the UNICEF Middle East and North Africa Region but not the WHO Eastern Mediterranean 
Region.
c Both northern and southern Sudan AIDS programmes were invited to participate in the review.
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on the prevention of mother-to-child 
HIV transmission), while 7 covered 
more than one topic. Most participating 
countries had started to develop HIV 
clinical guidelines only in 2006 or later. 
Eighteen reviewers, who were divided 
into five teams, carried out a minimum 
of two methodological and two content 
evaluations for each set of guidelines, 
except for guidelines on the prevention of 
mother-to-child HIV transmission from 
national AIDS programme I and for the 
comprehensive guidelines from national 
AIDS programme J (Table 2).
Quality of the guideline 
development methodology
A total of 51 appraisals of the guideline 
development methodology were available 
for analysis. Standardized mean scores on 
the five quality domains for each of the 
guidelines are shown in Table 2.
Table 1. Scores on items of the methodology appraisal toola for 20 clinical practice guidelines on human immunodeficiency virus 
(HIV) infection from countries in the eastern Mediterranean,b 2009
Appraisal item Median scorec
Scope and purpose domain (4 items)
1 The overall objective of the guidelines is specifically described. 3.63
2 The clinical questions covered by the guidelines are specifically described. 3.63
3 The patients to whom the guidelines are meant to apply are specifically described. 3.42
4 The level of care at which the guidelines are to be used is indicated. 3.00
Stakeholder involvement domain (6 items)
5 The guideline development group includes individuals from all relevant professional groups. 3.00
6 A list of individuals involved in developing the guidelines and their professional background or affiliation is 
provided.
2.88
7 The guidelines identify the agencies responsible for their development and ratification. 3.42
8 The patients’ views and preferences have been sought and the method used to do this is described. 1.75
9 The target users (i.e. professional groups) of the guidelines are clearly defined. 3.50
10 Potential conflicts of interest among committee members or funding or support agencies have been 
declared, taken into account and listed.
1.00
Rigour of development domain (9 items)
11 Systematic and satisfactory methods were used to select and analyse reference guidelines. 3.00
12 Systematic and satisfactory methods were used to search for national data and best practice. 2.50
13 The methods (i.e. consensus techniques) used to formulate the recommendations are clearly described. 2.40
14 The health benefits, side-effects and risks of treatment have been considered in formulating the 
recommendations.
3.17
15 There is an explicit link between the recommendations and supporting reference guidelines. 2.33
16 The guidelines were externally reviewed by experts before their publication. 2.50
17 The guidelines were piloted among target users. 2.50
18 A procedure for updating the guidelines is provided. 2.00
19 A review form (with an e-mail address or named contact) is provided for users to send in comments. 1.00
Clarity and presentation (6 items)
20 The recommendations are specific and unambiguous. 3.00
21 The different options for managing the condition are clearly presented and ranked. 2.84
22 The guidelines identify and advise on unacceptable or ineffective current practice. 3.00
23 Key recommendations are easily identifiable. 3.00
24 The guidelines can be used and interpreted easily when reproduced in black and white. 3.67
25 The guidelines are supported by tools for their application. 2.50
Clinical applicability and flexibility domain (8 items)
26 The circumstances (clinical or nonclinical) in which alternative care and treatment options should be used 
are described in the guidelines.
3.00
27 The recommendations collectively cover all clinically relevant circumstances (including prevention when 
applicable, diagnostic processes, clinical management and referral).
2.59
28 The recommendations collectively cover all relevant laboratory matters related to the clinical subject of the 
guidelines.
3.00
29 The guidelines’ recommendations are consistent with each other (i.e. consistency between guidelines). 2.50
30 There are no internal inconsistencies in the guidelines. 3.13
31 The potential barriers to applying the recommendations have been discussed. 2.84
32 The guidelines present key review criteria that can be used to assess adherence to the guidelines. 2.67
33 The guidelines describe ethical issues likely to arise in using them. 2.00
a The methodology appraisal tool was based on the Appraisal of Guidelines Research and Evaluation (AGREE) instrument.
b Countries were in the Eastern Mediterranean Region of the World Health Organization or the Middle East and North Africa Region of the United Nations Children’s 
Fund.
c Items were scored using a 4-point Likert scale: 4 = strongly agree, 3 = agree, 2 = disagree and 1 = strongly disagree.
Bull World Health Organ 2011;89:442–450 | doi:10.2471/BLT.10.083790 445
Anja De Weggheleire et al. Peer review of national HIV clinical guidelines
Research
Overall, only one of the 20 clinical 
practice guidelines had a satisfactory 
score in all five quality domains. Never-
theless, the quality of the clinical practice 
guidelines was generally satisfactory in 
terms of their scope and purpose (me-
dian domain score: 0.82; interquartile 
range, IQR: 0.58–0.89) and clarity and 
presentation (median domain score: 
0.67; IQR: 0.50–0.78). However, about 
one-third of guidelines did not reach the 
domain score threshold of 0.60 in these 
two domains. The median score for the 
quality domain of rigour of develop-
ment, which was 0.45 (IQR: 0.34–0.55), 
indicates that there was a general failure 
to adhere to the appropriate criteria; 
only one set of guidelines scored higher 
than 0.60 on this domain. Scores on the 
domains of stakeholder involvement and 
applicability and flexibility were slightly 
better but remained poor overall: the 
median score was 0.54 (IQR: 0.42–0.63) 
and 0.57 (IQR: 0.45–0.69) for the two 
domains, respectively.
Median scores for the 20 sets of 
guidelines on all 33 items of the method-
ology appraisal tool are listed in Table 1. 
The median score was 2.0 or less for the 
following five items: seeking patients’ 
views and preferences; declaring potential 
conflicts of interest among guideline com-
mittee members; providing procedures 
for updating guidelines; providing a 
mechanism for guideline users to make 
comments; and describing ethical issues 
that may arise in applying the guidelines.
Content review and concordance 
with WHO recommendations
A total of 55 content appraisals were avail-
able for analysing concordance between 
the clinical content of the 20 submitted 
guidelines and WHO recommendations.
Fifteen of the 20 clinical practice 
guidelines cited WHO recommenda-
tions as one of their main references: 
10 cited WHO 2006 and 2007 recom-
mendations,3–6 while 5 cited WHO 2003 
recommendations.23 Two guidelines cited 
non-WHO guidelines as a principal refer-
ence, namely United States Department 
of Health and Human Services 2006 
guidelines,24 while no clear references 
were available for the remaining three 
guidelines. On the basis of the guideline 
content review, the guideline review 
group concluded that five sets of guide-
lines (25%) were clearly outdated and 
referred to WHO 2003 recommenda-
tions. None of the 20 guidelines had been 
amended with updates since their initial 
publication.
Application of the content verifica-
tion checklist to all 20 guidelines enabled 
the reviewers to assess the strengths and 
weaknesses of around half the national 
AIDS programmes in the WHO Eastern 
Mediterranean Region and the UNICEF 
Middle East and North Africa Region. 
There were striking recurrent weaknesses 
in the following areas: antiretroviral pro-
phylaxis for the prevention of mother-to-
child HIV transmission; HIV diagnosis 
in exposed infants; care and prevention 
Table 2. Scores on quality domains of the methodology appraisal toola for 20 clinical practice guidelines for human 
immunodeficiency virus (HIV) infection from national AIDS programmes in the eastern Mediterranean,b 2009
Review 
team
National 
AIDS 
programme
Guideline subjectc 
(publication year)
Mean quality domain scored
Scope and 
purpose
Stakeholder 
involvement
Rigour of 
development
Clarity and 
presentation
Applicability and 
flexibility
Team 1 A ART in adults (2007) 0.50 0.42 0.54 0.64 0.48
B Comprehensive (2006) 0.86 0.44 0.04 0.24 0.33
C Comprehensive (2008) 0.58 0.61 0.56 0.50 0.42
Team 2 D Comprehensive (2004) 0.81 0.67 0.23 0.30 0.24
E Comprehensive (2008) 0.97 0.70 0.52 0.78 0.65
Team 3 F PMTCT (2005) 0.89 0.59 0.43 0.67 0.38
OI (2006) 0.81 0.57 0.51 0.67 0.68
ART in adults (2008) 0.78 0.65 0.52 0.69 0.51
G PMTCT (2008) 0.96 0.61 0.44 0.85 0.81
Comprehensive (2005) 0.54 0.50 0.35 0.44 0.44
H Comprehensive (2009) 0.88 0.52 0.44 0.67 0.69
Team 4 I PMTCT (2009) 1.00 0.33 0.58 0.94 0.86
PEP (2006) 0.75 0.41 0.33 0.70 0.65
ART in children (2006) 0.57 0.47 0.35 0.94 0.73
J PMTCT (2006) 0.54 0.17 0.24 0.44 0.46
Comprehensive (2006) 0.83 0.39 0.33 0.50 0.63
Team 5 K PMTCT (2006) 0.83 0.56 0.57 0.78 0.60
ART in adults (2006) 0.85 0.69 0.58 0.70 0.53
ART in children (2006) 0.96 0.75 0.71 0.88 0.75
L ART in adults (2007) 0.50 0.33 0.47 0.57 0.52
AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; OI, opportunistic infection prevention and treatment; PEP, postexposure prophylaxis; 
PMTCT, prevention of mother-to-child HIV transmission.
a The methodology appraisal tool was based on the Appraisal of Guidelines Research and Evaluation (AGREE) instrument.
b Countries were in the World Health Organization Eastern Mediterranean Region or the United Nations Children’s Fund Middle East and North Africa Region.
c Comprehensive guidelines covered more than one topic: for example, they may have included recommendations on postexposure prophylaxis and on ART for adults 
and children.
d Standardized scores ranged from 0 (lowest) to 1 (highest). A score of 0.6 or more was regarded as indicating reasonable quality.
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interventions for people living with an 
HIV infection; management of the side-
effects of antiretrovirals; management of 
immune reconstitution syndrome associ-
ated with ART; monitoring patients on 
ART; treatment failure; and switching to 
second-line therapy. In addition, recom-
mendations on counselling, psychosocial 
support, non-occupational postexposure 
prophylaxis and treatment of special 
groups, such as individuals with HIV 
and tuberculosis coinfections, individu-
als with HIV and hepatitis B or C virus 
coinfections and injecting drug users, 
were covered either superficially or not 
at all by most guidelines.
For the concordance analysis of 
core recommendations on ART for 
adults, paediatric ART and the preven-
tion of mother-to-child HIV transmis-
sion, only guidelines or sections of 
guidelines that were relevant to the 
topic and not outdated were consid-
ered: seven guidelines dealt with adult 
ART, five with paediatric ART and 
seven with the prevention of mother-
to-child HIV transmission.
The decision to initiate ART in 
adults, whether pregnant or not, adoles-
cents and children was based on WHO 
clinical staging and the CD4 T-cell 
count in all but two countries. These 
two countries use a viral load cut-off of 
> 100 000 copies/mL. Five adult ART 
guidelines recommended that therapy 
should be started in asymptomatic 
adults as soon as the CD4 cell count 
drops below 200 cells/mm3; the remain-
ing two guidelines used a less stringent 
cut-off of 350 cells/mm3.
Three of the five paediatric guide-
lines recommended that 2008 WHO 
revised criteria should be used to decide 
when ART should be started in infants 
and children: i.e. when the proportion 
of CD4 cells is < 15% in children aged 
5 years or more or < 20% in those aged 
between 12 and 59 months, and in all 
infants aged under 1 year with a con-
firmed HIV infection or presumptive 
severe HIV disease.16
The eligibility criteria for ART 
in pregnant women cited in the seven 
relevant guidelines were less concordant 
with WHO 2006 recommendations.4 
Three guidelines adopted WHO 2006 
recommendations or less stringent crite-
ria, one differed slightly by recommend-
ing “prophylaxis only” for all patients 
with clinical stage-I disease regardless 
of CD4 cell count and the remaining 
three did not specify any clear criteria.
Only one set of guidelines covering 
adult ART and one on the prevention 
of mother-to-child HIV transmission 
recommended first-line treatment 
with two nucleoside reverse transcrip-
tase inhibitors and a boosted protease 
inhibitor. The other 12 guidelines for 
these two patient groups recommended 
the first-line combination preferred 
by WHO : two nucleoside reverse 
transcriptase inhibitors and a non-nu-
cleoside reverse transcriptase inhibitor. 
Nine guidelines from seven countries 
recommended that first-line ART for 
adults, whether pregnant or not, should 
be based on the combination of zid-
ovudine and lamivudine, which is one 
of the backbones of nucleoside reverse 
transcriptase inhibitor treatment pre-
ferred by WHO, rather than on other 
possible combinations of nucleoside re-
verse transcriptase inhibitors. Stavudine 
was recommended in cases where there 
was zidovudine toxicity by seven guide-
lines from five countries but only one 
set of adult ART guidelines adopted 
the modified stavudine dosage recom-
mendation.22 Three of the seven adult 
ART guidelines singled out efavirenz as 
the non-nucleoside reverse transcriptase 
inhibitor of choice for adults who are 
not pregnant. In three other guidelines, 
no preference was specified and one 
opted for a boosted protease inhibitor 
regimen.
Three of the five sets of paediat-
ric guidelines recommended that the 
first-line regimen in infants should 
take into account previous exposure to 
non-nucleoside reverse transcriptase 
inhibitors. The other two sets of guide-
lines still recommended treatment with 
two nucleoside reverse transcriptase 
inhibitors and a non-nucleoside reverse 
transcriptase inhibitor for all infants 
regardless of their previous exposure to 
antiretroviral drugs. All guidelines rec-
ommended treatment with two nucleo-
side reverse transcriptase inhibitors and 
a non-nucleoside reverse transcriptase 
inhibitor for children aged over 1 year 
who are starting ART.
Guidance on HIV diagnosis in 
children aged under 18 months was 
adapted correctly from WHO generic 
guidelines in two of the five sets of 
paediatric guidelines. In the other three, 
misinterpretations led to ambiguous 
and incorrect recommendations.
In three of the seven sets of guide-
lines on the prevention of mother-to-
child HIV transmission, recommenda-
tions on antiretroviral prophylaxis for 
pregnant women who are not eligible 
for ART for their own health failed 
to comply with WHO 2006 recom-
mendations:4 one did not provide any 
guidance on prophylaxis, one had an 
inconsistency between the text and tables 
and one omitted the administration of 
zidovudine and lamivudine for 7 days fol-
lowing peripartum single-dose nevirapine.
Review process evaluation
Generally, the reviewers liked the meth-
odolog y appraisal tool based on the 
AGREE instrument and found it easy 
to use. Moreover, the adaptations made 
to the original AGREE instrument by 
integrating items from the UNAIDS 
document on developing HIV guidelines 
and by attempting to fit other AGREE 
items to the particularities of national 
guideline development were felt to be ap-
propriate for the purpose of this review.13 
The lack of information on the guideline 
development process in most guideline 
documents would have made it difficult 
to award a score using the appraisal tool if 
information from country questionnaires 
had not been available.
The methodology appraisal tool was 
also useful for increasing the reviewers’ 
awareness of potential common biases 
that may have affected the validity of the 
guidelines, e.g. the exclusion of some pro-
fessional groups and conflicts of interest. 
The guideline review group recognized 
that the methodology appraisal tool could 
be used as a guide for comprehensive 
methodological appraisals or as a check-
list for development committees during 
guideline development and adaptation.
The content concordance checklist 
was more cumbersome and time-con-
suming to use, particularly with outdated 
guidelines, guidelines that consisted only 
of flowcharts and guidelines whose 
structure was completely different from 
the WHO global guidelines. Only two 
guidelines had a similar structure and 
format, including the order of chapters, as 
the WHO 2006 generic guidelines, which 
made content verification for this review 
much more straightforward. Neverthe-
less, reviewers generally appreciated the 
comprehensiveness of the checklist as it 
enabled them to become familiar with 
WHO generic guidelines while identify-
ing gaps in the country guidelines.
The guideline review group also felt 
that the whole process, from the initial 
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meetings to discuss and plan for the re-
view to the consensus meeting at which 
results were shared, has enhanced the 
region’s capacity to develop methodologi-
cally and technically valid HIV clinical 
care guidelines in the future.
During the consensus meeting, the 
guideline review group formulated a set of 
pragmatic recommendations which we be-
lieve will enable countries to produce more 
current, coherent, correct, comprehensive 
and customized (i.e. 5 Cs) national clini-
cal practice guidelines (available from: 
http://telemedicine.itg.be/telemedicine/
uploads/recommendations.pdf ).
Discussion
The appraisal tools used in this review 
enabled the development methodol-
ogy and clinical content of HIV clinical 
practice guidelines to be evaluated in 
detail. Overall, the review’s findings con-
firm that translating WHO global HIV 
clinical care recommendations into valid, 
evidence-based, context-specific and 
up-to-date national guidelines remains a 
major challenge.
We identified important gaps in the 
guideline development methodology in 
19 of the 20 guidelines reviewed. Weak-
nesses principally concerned the meth-
ods used to select and analyse reference 
guidelines and the formulation of tailored 
recommendations (both of which were 
assessed by the rigour-of-development do-
main of the methodology appraisal tool), 
the extent to which guidelines represented 
the views of their intended users (assessed 
by the stakeholder-involvement domain) 
and the extent to which the implications 
of applying the guidelines were considered 
and taken into account (assessed by the 
applicability-and-flexibility domain).
The clinical content of a quarter of 
the guidelines evaluated was mainly out of 
date, even though the guidelines were still 
officially in use. For most of the remain-
der, the coherence and comprehensive-
ness of the recommendations were limited 
because guideline development was not 
rigorous enough and guidelines were not 
sufficiently adapted to their context.
In some cases, the absence of one 
or more clearly stated principal refer-
ence guidelines led to incoherent and 
incomplete recommendations. Moreover, 
generic reference guidelines that gave 
complex recommendations or recom-
mendations involving several options also 
tended to result in erroneous or unclear 
national guidelines. In particular, sec-
tions of WHO guidelines that presented 
several management options and lacked 
clear-cut recommendations were more 
likely to be poorly adapted.
Overall, the review group felt that 
WHO global recommendations may not 
result in better clinical care unless efforts 
are made at global, regional and national 
levels to help countries keep up with 
the pace of change and ensure that their 
national guidelines are of a sufficiently 
high quality.
As a result, we devised a set of rec-
ommendations for developing national 
clinical practice guidelines (available 
from: http://telemedicine.itg.be/tele-
medicine/uploads/recommendations.
pdf ). These recommendations were 
made in the knowledge that national 
AIDS programmes were planning to 
revise their HIV clinical practice guide-
lines to take account of the 2010 revised 
WHO recommendations on ART in 
adults, paediatric ART, the prevention 
of mother-to-child HIV transmission 
and infant feeding in the context of HIV 
infection.25–28 Some of our recommenda-
tions had previously been suggested by 
other groups.29
Previous papers have reported only 
on the concordance between key recom-
mendations in WHO reference publica-
tions and national guidelines. This is the 
first paper to describe the methodologi-
cal problems that arise when countries 
translate generic recommendations into 
contextualized national clinical practice 
guidelines. It is also the first paper to 
report on the application of an adapted 
AGREE instrument to HIV clinical 
practice guidelines.
The guideline review group con-
cluded that the methodology appraisal 
tool based on the AGREE instrument 
and used in this review is a user-friendly 
tool for guideline appraisal and can serve 
as a checklist of essential methodological 
issues that should be taken into account 
during guideline development.
Conclusion
This review highlights the prevailing 
lack of a systematic approach to adapting 
national HIV clinical practice guidelines 
from generic global recommendations. 
In particular, national guideline devel-
opment committees find it difficult to 
achieve an acceptable degree of rigour 
during guideline development and to 
customize guidelines adequately to the 
local context while ensuring the accuracy 
of the clinical content.
The impact of generic international 
guidelines could be maximized by paying 
more attention to and putting more effort 
into the development of national adapta-
tions. To this end, clearly identifying core 
recommendations, recommendations in 
revised guidelines that differ from those 
in previous guidelines and recommenda-
tions that depend most on the context 
would be helpful, as would the develop-
ment of templates for regional or national 
guideline adaptation.
We believe that future guideline 
development in the WHO Eastern Medi-
terranean and UNICEF Middle East and 
North Africa regions will benefit from the 
review process and we encourage other 
regions to launch similar initiatives since 
many will face comparable challenges 
with guideline development. ■
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صخلم
طسوتلما قشر نم ةبستكلما تابرخلا :يشربلا يعانلما زوعلا سويرفل ةينطو ةيداشرإ لئلاد دادعإ مامأ تايدحتلا
 ةينطولا  ةيداشرلإا  لئلادلل  يريسرلا  ىوتحلما  دادعإ  ةيلمع ةعجارم  ضرغلا
 قشر ميلقإ نادلبل يشربلا يعانلما زوعلا سويرفب ةصاخلا ةيريسرلا ةسرماملل
.ةمءاولماو دادعلإل ةيلبقتسم تايصوت ةغايصلو طسوتلما
 ةحصلا  ةمظنلم  طسوتلما  قشر ميلقإ  في  ًادلب  نوشرعو ةثلاث  يعد  ةقيرطلا
 ةدحتلما  مملأا  قودنصل  ايقيرفأ  لماشو  طسولأا  قشرلا  ميلقإو  ةيلماعلا
 سويرفب  ةصاخلا  ةيريسرلا  تاسرماملل  ةيداشرلإا  اهلئلاد  ميدقتل  ةلوفطلل
 ةيجهنلما  ةيلمعلا  مييقت  ىرجو  .اهتعجارلم  كلذو  يشربلا  يعانلما  زوعلا
 مييقتو  ثوحب  ةعجارم  ىوتحمو  ةادأ  مادختساب  ةيداشرلإا  لئلادلا  دادعلإ
 لئلادلا عم اهمؤاوت ىدم مييقتل ةيدقفت ةئماق مادختسابو ،ةيداشرلإا لئلادلا
.2006 ماعل ةيلماعلا ةحصلا ةمظنلم ةيكللما ةدودحلما يرغ ةيداشرلإا
 يماع ينب مهدادعإ ىرج ًايداشرإ ًلايلد نيشرع ًادلب شرع انثا  مدق جئاتنلا
 لاجم  في )0.6  نم  لقأ  يأ(  ًافيعض زارحلأا  طيسو تناكو  .2009  و  2004
 ةيناكمإو ،ةينعلما تاهجلا ةكراشمو ،ةقدلا ثيح نم دادعلإا ةيجهنم ةدوج
 :طيسولا( ضرغلاو قاطنلا تلااجم في لضفأ زارحلأا تناكو .ةنورلماو ،قيبطتلا
 ضرعلاو  حوضولاو  )-0.89  0.58  :ينتيعبرلا  ينتحيشرلا  ينب  ىدلما  ،0.82
 صخي ام فيو .)0.78-0.50 :ينتيعبرلا ينتحيشرلا ينب ىدلماو ،0.67 :طيسولا(
 لهأتلا يرياعمو هب صىولما لولأا طخلا جلاع ناكف ،يداشرلإا ليلدلا ىوتحم
 لئلادلا ةيبلاغ في ةيلماعلا ةحصلا ةمظنم تايصوت عم ًاقفاوتم ينغلابلل جلاعلل
 ةيرقهقلا  تاسويرفلا  تاداضبم  ةيقوتلا  لوح  تايصوتلا  نأ  لاإ  .ةيداشرلإا
 ىودعلا  جلاعو  صيخشتو  ،سويرفلاب  سيأرلا  ىودعلا  لاقتنا  نم  ةياقولل
 ينجلاعلما  ضىرلما  دصرو ،عّضرلا  لافطلأا  ينب  يشربلا  يعانلما  زوعلا  سويرفب
 ىودعلل  ةبحاصلما  ضارملأاو  جلاعلا  لشفو  ،ةيرقهقلا  تاسويرفلا  تاداضبم
.ةيداشرلإا لئلادلا ةيبلاغ في ةدوقفم تناك
 ةيداشرلإا  لئلادلا  نم ىمظعلا  ةيبلاغلا  في يجهنم  فعض كانه جاتنتسلاا
 لىإ  نادلبلا  جاتحتو  .اهاوتحم  ةقد  مدعو  ةيريسرلا  تاسرماملل  ةينطولا
 اهتثادحو  ةيداشرلإا  لئلادلا  ةيقودصم  نماضل  ةمءاولما  ةيلمع  في  ةدعاسلما
 ةياعرلا  لوح  ةيلماعلا  ةحصلا  ةمظنلم  ةيلماعلا  تايصوتلل  اهضارعتسا  ةقدو
.يشربلا يعانلما زوعلا سويرفب ينباصلما ضىرملل ةيريسرلا
摘要
开发全国HIV临床实践指南面临的挑战：来自东地中海国家的经验
目标 评估东地中海国家全国人类免疫缺陷病毒（HIV）临
床实践指南的开发过程和临床内容，并给出将来指南开发
和修改的建议。
方法 邀请了世界卫生组织（WHO）东地中海区域和联合
国儿童基金会中东和北非区域的23个国家提交全国HIV
临床实践指南，以供审查。采用经修改的指南研究和评
价的评审工具，对指南开发方法进行了评估；至于指南
内容，采用清单的形式评价其是否符合WHO 2006年一
般性指南的要求。
结果 十二个国家提交了从2004年到2009年期间开发的
20份指南。在开发严格性、相关利益方参与程度以及适
用性和灵活性的方法学质量上，平均得分较低（< 0.6）
。在范围和目的性以及清晰程度和呈现方式上的得分稍
高（前者：平均得分：0.82，四分位差IQR：0.58－0.89
；后者：平均得分：0.67，IQR：0.50－0.78）。至于指
南内容，大多数指南的成年人抗逆转录病毒疗法（ART）
首要治疗建议和合格标准都符合WHO的建议。但是，经
常缺少HIV垂直传播预防要求的抗逆转录酶病毒预防、幼
儿感染HIV的诊断和治疗、ART病人的监控、治疗失败以
及共同发病率的建议。
结论 大部分全国HIV临床实践指南在方法学上存在缺陷，
并且存在内容错误。许多国家需要得到修改流程的相关帮
助，确保指南的有效性和及时性，并能准确反映WHO对
HIV病人的全球临床关爱建议。
Résumé
Défis du développement de recommandations nationales sur le VIH: l’expérience des pays de l’Est de la 
Méditerranée
Objectif Évaluer le processus de développement et le contenu 
clinique des recommandations pour la pratique clinique sur le virus de 
l’immunodéficience humaine (VIH) des pays de l’Est de la Méditerranée, 
et formuler des directives pour le développement et l’adaptation des 
futures recommandations.
Méthodes Vingt-deux pays de l’Est de la Méditerranée de l’Organisation 
mondiale de la Santé (OMS) et de régions d’Afrique du Nord et du Moyen-
Orient de l’United Nations Children’s Fund (UNICEF) ont été invités à 
soumettre leurs recommandations pour la pratique clinique nationales 
sur le VIH en vue de les évaluer. La méthodologie de développement des 
recommandations a été évaluée en utilisant une adaptation du contenu des 
recommandations et de la grille AGREE (Appraisal of Guidelines Research 
and Evaluation) à l’aide d’une liste de contrôle permettant d’évaluer la 
concordance avec les directives génériques OMS 2006.
Résultats Douze pays ont soumis 20 recommandations développées 
entre 2004 et 2009. Les notes moyennes étaient mauvaises (< 0,6) pour 
les domaines de qualité méthodologique de la rigueur du développement, 
de l’implication et de l’applicabilité des parties prenantes et de la flexibilité. 
Les notes étaient meilleures pour les domaines des compétences et 
des objectifs (moyenne: 0,82, intervalle interquartile, IQR: 0,58–0,89), 
de la clarté et de la présentation (moyenne: 0,67, IQR: 0,50–0,78). 
En ce qui concerne le contenu des recommandations, le traitement de 
première intention conseillé et les critères d’éligibilité en matière de 
thérapie antirétrovirale (TAR) chez les adultes étaient alignés sur les 
directives de l’OMS dans la plupart des recommandations. Cependant, 
des recommandations sur la prophylaxie antirétrovirale pour la prévention 
de la transmission verticale du VIH, le diagnostic et le traitement de 
l’infection par le VIH chez les enfants en bas âge, la surveillance des 
patients suivant une TAR, l’échec thérapeutique et les comorbidités étaient 
souvent manquantes.
Conclusion La grande majorité des recommandations pour la pratique 
clinique sur le VIH présentait des défauts de méthodologie et des 
inexactitudes de contenu. Les pays nécessitent une assistance dans le 
processus d’adaptation afin de garantir que les recommandations sont 
valables et à jour et qu’elles reflètent précisément les directives globales 
des soins cliniques de l’OMS pour les patients porteurs du VIH.
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Резюме
Проблемы разработки национальных руководств по ВИЧ: опыт стран восточного 
Средиземноморья
Цель Дать оценку процессу разработки и клиническому 
содержанию национальных руководств по клинической 
практике в области вируса иммунодефицита человека 
(ВИЧ), и сформулировать рекомендации по разработке и 
адаптации руководств в будущем.
Методы В 23 страны региона Всемирной организации 
здравоохранения (ВОЗ) для с тран Вос точного 
Средиземноморья и региона Детского фонда ООН для стран 
Ближнего Востока и Северной Африки была направлена 
просьба представить для обзора национальные руководства 
по клинической практике в области ВИЧ. Методологии 
разработки конкретных руководств оценивались с помощью 
Опросника по экспертизе и аттестации руководств (AGREE) 
и с учетом содержания руководств; для оценки соответствия 
общему руководству, разработанному ВОЗ в 2006 году, 
использовался перечень контрольных вопросов.
Результаты Двадцать стран представили 20 руководств, 
разработанных в период с 2004 по 2009 год. Медианные 
балльные оценки были низкими (т. е. ниже 0,6) для 
следующих областей методологического качества: 
тщательность разработки; участие заинтересованных 
сторон; возможность внедрения и гибкость. Более 
высокими были баллы для областей применения и цели 
(медиана: 0,82, межквартильный размах, МКР: 0,58–0,89), 
ясности изложения и формы представления (медиана: 0,67, 
МКР: 0,50–0,78). Что касается содержания руководства, 
рекомендуемого метода лечения первого выбора и 
критериев допустимости применения антиретровирусной 
терапии (АРТ) у взрослых, то они в большинстве руководств 
соответствовали рекомендациям ВОЗ. Вместе с тем, зачастую 
отсутствовали рекомендации по антиретровирусной 
профилактике вертикальной передачи ВИЧ-инфекции, 
диагностике и лечению ВИЧ-инфекции у детей в возрасте до 
1 года, мониторингу больных, получающих АРТ, неудачному 
исходу лечения и коморбидности.
Вывод Значительное большинство национальных 
руководств по клинической практике в области ВИЧ имеют 
методологические недостатки и содержат неточности. Для 
того чтобы руководства были достоверными, отвечали 
современным требованиям и точно отражали общие 
рекомендации ВОЗ по оказанию клинической помощи 
пациентам с ВИЧ, странам необходимо оказывать 
содействие в процессе адаптации.
Resumen
Retos en el desarrollo de unas directrices nacionales en relación al VIH: la experiencia del Mediterráneo 
Oriental
Objetivo Evaluar el proceso de desarrollo y el contenido clínico 
de las directrices nacionales sobre práctica clínica del virus de 
inmunodeficiencia humana (VIH) en países del Mediterráneo Oriental 
y formular recomendaciones para el desarrollo y la adaptación de las 
directrices futuras.
Métodos Se propuso a 23 países de la Región del Mediterráneo Oriental 
de la Organización Mundial de la Salud (OMS) y de las regiones del Norte 
de África y Oriente Medio de Unicef que enviaran sus directrices nacionales 
sobre la práctica clínica de VIH para su revisión. Se evaluó el método de 
desarrollo de las directrices, empleando una adaptación del instrumento 
Appraisal of Guidelines Research and Evaluation (AGREE) y se analizó el 
contenido de las directrices empleando una lista de comprobación para 
evaluar su afinidad con las directrices generales de la OMS del 2006.
Resultados Doce países enviaron 20 directrices desarrolladas entre los 
años 2004 y 2009. Las puntuaciones medias resultaron bajas (< 0,6) en 
los dominios de calidad metodológica del rigor de desarrollo, la implicación 
de los participantes y la aplicabilidad y flexibilidad. Se obtuvieron mejores 
puntuaciones para los dominios de objetivo y finalidad (media: 0,82, 
rango intercuartil, RIC: 0,58–0,89) y claridad y presentación (media: 
0,67, RIC: 0,50–0,78). En lo relativo al contenido de las directrices, los 
tratamientos de primera línea recomendados y los criterios de elegibilidad 
para el tratamiento con antirretrovirales (TAR) en adultos se adherían a 
las recomendaciones de la OMS en la mayoría de las directrices. No 
obstante, a menudo faltaban datos sobre recomendaciones en cuanto a 
la profilaxis antirretroviral para la prevención de la transmisión vertical del 
VIH, el diagnóstico y el tratamiento de la infección por el VIH en lactantes, 
el control de los pacientes sometidos al tratamiento con antirretrovirales, 
los fracasos terapéuticos y las comorbilidades.
Conclusión La amplia mayoría de las directrices nacionales sobre la 
práctica clínica del VIH mostraron deficiencias metodológicas y faltas de 
precisión en su contenido. Los países necesitan ayuda con el proceso 
de adaptación para garantizar que las directrices sean válidas, estén 
actualizadas y reflejen de manera precisa las recomendaciones de la 
OMS sobre los cuidados clínicos globales para los pacientes con el VIH.
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